The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma
Open accessAbstract
Anaplastic thyroid cancer (ATC) is a devastating disease with a dismal prognosis. Patients who have disease confined to the thyroid and who are able to undergo complete surgery and chemoradiation stand the best chance for survival. Unfortunately, nearly 50% of patients have distant metastases at diagnosis, and most present with locally advanced, unresectable tumors. Nevertheless, BRAF-mutated ATC patients represent a subset of cases who can benefit from a combination therapy with BRAF and MEK inhibitors. Here, a patient is presented with end-stage, locally advanced, unresectable ATC who was treated with this combination. Immunotherapy with pembrolizumab was added at the first sign of progression after which he achieved a partial response to therapy, enabling a complete surgical resection followed by postoperative chemoradiation to be undertaken. This novel neoadjuvant approach to BRAF-mutated ATC should be studied in further in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature · doi:10.1038/nature22079 · Cited by 1,664
Lanman, R. B., Mortimer, S. A., Zill, O. A., Sebisanovic, D., Lopez, R., Blau, S., Collisson, E. A., Divers, S. G., Hoon, D. S. B., Kopetz, E. S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140712 · Cited by 695
Cited by
Bible, K. C., Kebebew, E., Brierley, J., Brito, J. P., Cabanillas, M. E., Clark, T. J., Di Cristofano, A., Foote, R., Giordano, T., Kasperbauer, J., et al. (2021) · Thyroid · doi:10.1089/thy.2020.0944 · Cited by 730
Self-citationEvaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019
Maniakas, A., Dadu, R., Busaidy, N. L., Wang, J. R., Ferrarotto, R., Lu, C., Williams, M. D., Gunn, G. B., Hofmann, M.-C., Cote, G., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.3362 · Cited by 382
Self-citationTargeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond
Cabanillas, M. E., Ryder, M., & Jimenez, C. (2019) · Endocrine Reviews · doi:10.1210/er.2019-00007 · Cited by 335
Self-citationWang, J. R., Zafereo, M. E., Dadu, R., Ferrarotto, R., Busaidy, N. L., Lu, C., Ahmed, S., Gule-Monroe, M. K., Williams, M. D., Sturgis, E. M., et al. (2019) · Thyroid® · doi:10.1089/thy.2019.0133 · Cited by 230
Self-citationShonka, D. C., Ho, A., Chintakuntlawar, A. V., Geiger, J. L., Park, J. C., Seetharamu, N., Jasim, S., Abdelhamid Ahmed, A. H., Bible, K. C., Brose, M. S., et al. (2022) · Head & Neck · doi:10.1002/hed.27025 · Cited by 117
Self-citation
Metadata
- Authors
- Cabanillas, M. E., Ferrarotto, R., Garden, A. S., Ahmed, S., Busaidy, N. L., Dadu, R., Williams, M. D., Skinner, H., Gunn, G. B., Grosu, H., Iyer, P., Hofmann, M. C., & Zafereo, M.
- Venue
- Thyroid
- Publisher
- SAGE Publications
- Published
- 2018-07
- Volume
- 28
- Issue
- 7
- Pages
- 945-951
- ISSN
- 1050-7256 (ISSN-L)
- 1557-9077
- OpenAlex
- W2801407670
- Cited by
- 159
- References
- 2
- FWCI
- 12.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.